Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, January 2006

Sort by: Newest first Oldest first A-Z Z-A

  • Cash for access

    28 JAN 2006 0:00

    The Department of Health has allocated over £650m a year to a five-year strategy to give patients better access to new medicines and treatments, and to support researchers conducting health and social care research throughout England. Part of the scheme will mean that every patient in England will haveaccess to clinical trials and have the opportunity to participate in studies.

  • Society's grant funding from Government far outstrips that of other health regulators

    28 JAN 2006 0:00

    Grant funding paid to the Royal Pharmaceutical Society by the Department of Health far outstrips the sums given to other health regulators, as revealed in a Parliamentary written answer last week. The Society has questioned the figures.

  • Ministers may decide Society must separate its functions

    28 JAN 2006 0:00

    Ministers are considering whether to allow the Royal Pharmaceutical Society to continue to have both professional and regulatory roles or to require the Society to come into line with the majority of other health professional regulators.

  • Supervision plans may push up insurance

    28 JAN 2006 0:00

    Government plans to allow community pharmacies to operate without a pharmacist on the premises will inevitably affect liability, insurance providers warned this week. The Chemists’ Defence Association said it was essential that any moves towards expanding the pharmacists’ professional role must not compromise patient safety.

  • NICE consults on Alzheimer's disease drugs

    28 JAN 2006 0:00

    A revised draft of a National Institute for Health and Clinical Excellence review of Alzheimer's disease treatments is recommending that donepezil (Aricept), galantamine (Reminyl) and rivastigmine (Exelon) should be considered as options for patients with moderately severe disease only (patients with a score of between 10 and 20 points on the mini mental state examination).

  • Episodic antiretroviral treatment harms patients

    28 JAN 2006 0:00

    Enrolment of subjects in a large international HIV/AIDS trial to compare episodic with continuous antiretroviral treatment has ceased. The decision follows an analysis of interim study data, which showed that subjects on episodic treatment had more than twice the risk of disease progression compared with those taking continuous antiretroviral therapy.

  • Under-16s confidentiality upheld

    28 JAN 2006 0:00

    AJ Photo/Science Photo Library Confidentiality will be respected

  • Cholinesterase inhibitors may help in mild Alzheimer's

    28 JAN 2006 0:00

    Cholinesterase inhibitor drugs donepezil (Aricept), galantamine (Reminyl) and rivastigmine (Exelon) can provide improved cognitive function, daily activity and behaviour to Alzheimer's disease patients with mild to moderate dementia, according to a review published online in The

  • HIV regimens for treatment-naive patients compared

    28 JAN 2006 0:00

    Treatment regimens Patients received either efavirenz (Sustiva) 600mg plus tenofovir disoproxil (Viread) 300mg and emtricitabine (Emtriva) 200mg once daily, or efavirenz 600mg once daily plus a fixed dose of zidovudine 300mg and lamivudine 150mg twice daily (Combivir).

  • Suspected ADRs increase

    28 JAN 2006 0:00

    Last year there were 1,013 deaths linked to adverse drug reaction (ADR) reports, up from 857 in 2004, health minister Jane Kennedy revealed last week.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.